Castle Biosciences INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Castle Biosciences reported a net loss of $24.2 million in 2025, a significant reversal from the prior year's profit, despite a 3.7% increase in total net revenues driven by non-dermatologic tests.
NASDAQ
Castle Biosciences reported a return to profitability and a 51% revenue increase for the fiscal year 2024, fueled by its dermatology and gastroenterology tests, though future results face uncertainty due to an impending Medicare non-coverage decision for its DecisionDx-SCC test.
NASDAQ
10-K: Castle Biosciences Reports Full Year 2023 Results, Highlights Growth and Strategic Initiatives
Castle Biosciences' 2023 annual report showcases significant revenue growth, driven by its dermatologic testing franchise and strategic acquisitions, while also detailing ongoing challenges and future pipeline developments.